Skip to main content

Advertisement

SpringerLink
Log in

The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: A meta- analysis

  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To examine the association between the sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer.

Method

Meta-analysis of case-control studies using a random effects model. The “Main outcome measure” was the odds ratio for the risk of lung cancer, using extensive metabolisers as the reference group.

Results

Thirteen studies were identified. The studies were too heterogeneous to be pooled the size of the odds ratio increased with the sample size. When the analysis was restricted to the largest studies, there was no difference in risk between poor and extensive metabolisers (odds ratio 0.95, 95% confidence interval 0.68–1.33).

Conclusion

No association was found between the CYP2D6 oxidation polymorphism and lung cancer risk when sample size bias was taken into account.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Doll R, Payne P, Waterhause J (1987) Cancer incidence in five continents. IARC Scientific Publications, 15, 42, 88, Berlin

    Google Scholar 

  2. Doll R, Peto R, Wheatley K, Gray R, Sutherland I (1994) Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ 309: 901–911

    PubMed  CAS  Google Scholar 

  3. Doll R, Peto R (1981) The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66: 1191–1208

    PubMed  CAS  Google Scholar 

  4. Nebert DW (1991) Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk. Cancer Cell 3: 93–96

    CAS  Google Scholar 

  5. Idle JR, Armstrong M, Boddy AV, Boustead C, Cholerton S, Cooper J, Daly AK, Ellis J, Gregory W, Hadidi H, Höfer C, Holt J, Leathart J, McCracken N, Monkman SC, Painter JE, Taber H, Walker D, Yule M (1992) The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics 2: 246–258

    Article  PubMed  CAS  Google Scholar 

  6. Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ (1991) A tobacco smoke-derived nitrosamine, 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone, is activated by multiple human cyto- chrome P450s including the polymorphic human P4502D6. Carcinogenesis 12: 1197–1201

    Article  PubMed  CAS  Google Scholar 

  7. Penman BW, Reece J, Smith T, Yang CS, Gelboin HV, Gonzalez FJ, Crespi CL (1993) Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics 3: 28–39

    Article  PubMed  CAS  Google Scholar 

  8. Brøsen K, Gram LF (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36: 537–547

    Article  PubMed  Google Scholar 

  9. Zanger UM, Vilbois F, Hardwick JP, Meyer UA (1988) Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27: 5447–5454

    Article  PubMed  CAS  Google Scholar 

  10. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529–532

    Article  PubMed  CAS  Google Scholar 

  11. Kato S, Bowmann ED, Harrington AM, Blomeke B, Shields PG (1995) Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst 87: 902–907

    Article  PubMed  CAS  Google Scholar 

  12. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Controlled Clin Trials 7: 177–188

    Article  PubMed  CAS  Google Scholar 

  13. Agúndez JAG, Martinez C, Ladero JM, Ledesma MC, Ramos JM, Martin R, Rodriguez A, Jara C, Benitez J (1994) Debrisoquine oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther 55: 10–14

    PubMed  Google Scholar 

  14. Benitez J, Ladero JM, Jara C, Carrillo JA, Cobaleda J, Llerena A, Vargas E, Munoz JJ (1991) Polymorphic oxidation of debrisoquine in lung cancer patients. Eur J Cancer 27: 158–161.

    Article  PubMed  CAS  Google Scholar 

  15. Caporaso NE, Tucker MA, Hoover RN, Hayes RB, Pickle LW, Issaq HJ, Muchik GM, Gree-Gallo L, Buivys D, Aisner S, Resau JH, Trump BF, Tollrud D, Weston A, Harris CC (1990) Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 82: 1264–1272

    Article  PubMed  CAS  Google Scholar 

  16. Duche JC, Barre J, Cremoux Hde, Dalphin JC (1991) Lack of relationship between the polymorphism of debrisoquine oxidation and lung cancer. Br J Clin Pharmacol 31: 533–536

    PubMed  CAS  Google Scholar 

  17. Faccini GB, Puchetti V, Zatti N (1990) Dextromethorphan oxidation phenotypes as markers for susceptibility to lung cancer. Clin Chem 36: 387

    PubMed  CAS  Google Scholar 

  18. Hirvonen A, Husgafvel Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H (1993) PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 3: 19–27

    Article  PubMed  CAS  Google Scholar 

  19. Horsmans Y, Desager JP, Harvengt C (1991) Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility? Biomed Pharmacother 45: 359–362

    Article  PubMed  CAS  Google Scholar 

  20. Law MR, Hetzel M, Idle J (1989) Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer 59: 686–687

    PubMed  CAS  Google Scholar 

  21. Roots I, Drakoulis N, Ploch M, Heinemeyer G, Loddenkemper R, Minks T, Nitz M, Otte F, Koch M (1988) Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. Klin Wochenschr 66: 87–97

    Article  PubMed  Google Scholar 

  22. Shaw GL, Falk RT, Deslauriers J, Frame JN, Nesbitt JC, Pass HI, Issaq HJ, Hoover RN, Tucker MA (1994) Debrisoquine metabolism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 4: 41–48

    Google Scholar 

  23. Speirs CJ, Murray S, Davies DS, Mabadeje AFB, Boobis AR (1990) Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol 29: 101–109

    PubMed  CAS  Google Scholar 

  24. Tefre T, Daly AK, Armstrong M, Leathart JBS, Idle JR, Brøgger A, Børresen A-L (1994) Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 4: 47–57

    Article  PubMed  CAS  Google Scholar 

  25. Wolf CR, Smith CA, Gough AC, Moss JE, Vallis KA, Howard G, Carey FJ, Mills K, McNee W, Carmichael J, Spurr NK (1992) Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 13: 1035–1038

    Article  PubMed  CAS  Google Scholar 

  26. Ayesh R, Idle J, Ritchie JC, Crothers MJ, Hetzel M (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312: 169–170

    Article  PubMed  CAS  Google Scholar 

  27. Hetzel MR, Law M, Keal EE, Sloan TP, Idle JR, Smith RL (1980) Is there a genetic component in bronchial carcinoma in smokers? Thorax 35: 709

    Article  Google Scholar 

  28. Roots I, Brockmoeller J, Drakoulis N, Loddenkemper R (1992) Mutant genes of cytochrome P-4502D6, gluthatione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients. Clin Invest 70: 307–319

    Article  CAS  Google Scholar 

  29. Roots I, Drakoulis N, Brockmöller J (1993) Still an open question: does active CYP2D6 predispose to lung cancer. 8th Int Conf on Cytochrome P450, Lisbon 159 (abstract)

  30. Stucker I, Cosme J, Laurent P, Cenee S, Beaune P, Bignon J, Depierre A, Milleron B, Hemon D (1995) CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. Carcinogenesis 16: 2759–2764

    Article  PubMed  CAS  Google Scholar 

  31. Pocock SJ, Hughes MD, Lee RJ (1987) Statistical problems in the reporting of clinical trials: a survey of three medical journals. N Engl J Med 317: 426–432

    PubMed  CAS  Google Scholar 

  32. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, Phil D, King D and the AZT collaborative working group (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind placebo-controlled trial. N Engl J Med 317: 185–191

    PubMed  CAS  Google Scholar 

  33. Aboulker J-P, Swart AM (1993) Preliminary analysis of the Concorde trial. Lancet 341: 889–890

    Article  PubMed  CAS  Google Scholar 

  34. Wolf CR, Smith CAD, Bishop T, Forman D, Gough AC, Spurr NK (1994) CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics 4: 104–106

    Article  PubMed  CAS  Google Scholar 

  35. London SJ, Daly AK, Thomas DC, Caporaso NE, Idle JR (1994) Methodological issues in the interpretation of studies of the CYP2D6 genotype in relation to lung cancer. Pharmacogenetics 4: 107–108

    Article  PubMed  CAS  Google Scholar 

  36. Alván G, Bechtel P, Iselius L, Gundert Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533–537

    Article  PubMed  Google Scholar 

  37. Bouchardy C, Benhamou S, Dayer P (1996) The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 56: 251–253

    PubMed  CAS  Google Scholar 

  38. Sacks H, Berrier J, Reitman D (1987) Meta-analyses of randomized controlled trials. N Engl J Med 316: 450–455

    PubMed  CAS  Google Scholar 

  39. Dickersin K, Berlin JA (1992) Meta-analysis: state-of-the-science. Epidemiol Rev 14: 154–176

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Institute of Medical Biology, Odense University, Winsløwparken 19, Dk-5000, Odense C, Denmark

    P. M. Christensen & K. Brøsen

  2. The Nordic Cochrane Centre, Rigshospitalet, Copenhagen

    P. C. Gøtzsche

Authors
  1. P. M. Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. C. Gøtzsche
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Brøsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Christensen, P.M., Gøtzsche, P.C. & Brøsen, K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: A meta- analysis. Eur J Clin Pharmacol 51, 389–393 (1997). https://doi.org/10.1007/s002280050219

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002280050219

Key words

Search

Navigation